![]() TEVAN 27 Nov 2017 Estimated | Other | MX$0.09 Per Share |
![]() TEVAN 27 Nov 2017 | Other | MX$0.09 Per Share |
![]() TEVAN 25 Aug 2017 | Other | MX$0.09 Per Share |
![]() TEVAN 1 Jun 2017 | Other | MX$0.34 Per Share |
![]() TEVAN 28 Feb 2017 | Other | MX$0.34 Per Share |
![]() TEVAN 1 Dec 2016 | Other | MX$0.34 Per Share |
6 May 2025 (15 Days) Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.7 Cons. EPS | 0.71 EPS |
6 Nov 2024 Date | | 0.65 Cons. EPS | 0.69 EPS |
31 Jul 2024 Date | | 0.55 Cons. EPS | 0.61 EPS |
8 May 2024 Date | | 0.51 Cons. EPS | 0.48 EPS |
![]() TEVAN 27 Nov 2017 Estimated | Other | MX$0.09 Per Share |
![]() TEVAN 27 Nov 2017 | Other | MX$0.09 Per Share |
![]() TEVAN 25 Aug 2017 | Other | MX$0.09 Per Share |
![]() TEVAN 1 Jun 2017 | Other | MX$0.34 Per Share |
![]() TEVAN 28 Feb 2017 | Other | MX$0.34 Per Share |
![]() TEVAN 1 Dec 2016 | Other | MX$0.34 Per Share |
6 May 2025 (15 Days) Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.7 Cons. EPS | 0.71 EPS |
6 Nov 2024 Date | | 0.65 Cons. EPS | 0.69 EPS |
31 Jul 2024 Date | | 0.55 Cons. EPS | 0.61 EPS |
8 May 2024 Date | | 0.51 Cons. EPS | 0.48 EPS |
Drug Manufacturers—Specialty & Generic Industry | Healthcare Sector | Mr. Richard D. Francis CEO | XMEX Exchange | US8816242098 ISIN |
Israel Country | 35,001 Employees | 12 Dec 2017 Last Dividend | 1 Jul 2004 Last Split | - IPO Date |
Teva Pharmaceutical Industries Limited is a prominent global company with a focus on developing, manufacturing, marketing, and distributing a wide range of pharmaceutical products. Its operations span across North America, Europe, Israel, and other international markets. Teva's portfolio includes generic medicines, specialty medicines, and biopharmaceutical products, catering to various dosage forms and therapeutic areas. With a history dating back to 1901, the company has established itself as a leader in the pharmaceutical industry, headquartered in Tel Aviv, Israel. Teva is known for its contribution to central nervous system (CNS), respiratory, and oncology therapeutic areas, providing active pharmaceutical ingredients and contract manufacturing services, alongside operating an out-licensing platform for other pharmaceutical companies. Teva's commitment to healthcare and therapeutic advancements is evident through its collaboration agreements with MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH.
BENDEKA and TREANDA injections: Used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, these injections underscore Teva's focus on oncology.
GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM: These products exemplify Teva's commitment to providing supportive care in oncology, including treatments for neutropenia and arsenic trioxide for leukemia.
COPAXONE: This flagship product for the treatment of relapsing forms of multiple sclerosis highlights Teva's innovation in CNS therapies.
AJOVY: A treatment for the preventive care of migraine in adults, AJOVY is part of Teva's specialty medicine range aimed at improving quality of life for migraine sufferers.
AUSTEDO: Focused on neurodegenerative and movement disorders, AUSTEDO is used for treating conditions associated with Huntington's disease and tardive dyskinesia.
UZEDY: This antipsychotic is used for the treatment of schizophrenia, reflecting Teva's ongoing development in CNS health.
Respiratory Products: Teva offers a suite of respiratory products like ProAir RespiClick inhalation powder, QVAR for asthma, BRALTUS, CINQAIR/CINQAERO injection, DuoResp Spiromax, and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder, addressing a broad spectrum of respiratory conditions.
OTC Products: Teva's over-the-counter (OTC) offerings under brands such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, cater to a variety of everyday health needs, from skincare to cold and flu relief.
In addition to its broad spectrum of pharmaceutical products, Teva Pharmaceutical Industries Limited also provides active pharmaceutical ingredients and contract manufacturing services, demonstrating its versatility and comprehensive approach to healthcare solutions.